BACKGROUND: There are limited data on the safety of periprocedural heparin in acute ischemic stroke endovascular therapy. METHODS: A post hoc analysis was performed on patients enrolled in the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial to compare baseline characteristics and clinical outcomes between patients who received periprocedural heparin (HEP(+)) with patients who did not receive periprocedural heparin (HEP(-)). Data on periprocedural heparin use or nonuse was collected on patients enrolled between February 1, 2006 and July 31, 2006. RESULTS: Of 51 patients included in the analysis cohort, 24 (47%) received periprocedural heparin with a median dose of 3000 U. Baseline and procedural characteristics were similar between the 2 groups, although HEP(+) patients were more likely to have vertebral or basilar occlusion than HEP(-) patients (16.7% v 0%; P = .04). There was no significant difference in rates of hemorrhage, procedural complications, or 90-day mortality between the 2 groups. In multivariable analysis, a 90-day good outcome (modified Rankin scale score of 0-2) was associated with age (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.86-0.98; P = .0104), final revascularization success (OR 6.86; 95% CI 1.39-33.81; P = .0179), and periprocedural heparin use (OR 5.89; 95% CI 1.34-25.92; P = .0189). CONCLUSIONS: In this small subgroup of the Multi MERCI trial, periprocedural heparin use in acute ischemic stroke endovascular therapy was not associated with increased rates of intracerebral hemorrhage or 90-day mortality. The improved 90-day good outcome among patients undergoing mechanical thrombectomy combined with periprocedural heparin warrants further study in a larger cohort.
BACKGROUND: There are limited data on the safety of periprocedural heparin in acute ischemic stroke endovascular therapy. METHODS: A post hoc analysis was performed on patients enrolled in the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial to compare baseline characteristics and clinical outcomes between patients who received periprocedural heparin (HEP(+)) with patients who did not receive periprocedural heparin (HEP(-)). Data on periprocedural heparin use or nonuse was collected on patients enrolled between February 1, 2006 and July 31, 2006. RESULTS: Of 51 patients included in the analysis cohort, 24 (47%) received periprocedural heparin with a median dose of 3000 U. Baseline and procedural characteristics were similar between the 2 groups, although HEP(+) patients were more likely to have vertebral or basilar occlusion than HEP(-) patients (16.7% v 0%; P = .04). There was no significant difference in rates of hemorrhage, procedural complications, or 90-day mortality between the 2 groups. In multivariable analysis, a 90-day good outcome (modified Rankin scale score of 0-2) was associated with age (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.86-0.98; P = .0104), final revascularization success (OR 6.86; 95% CI 1.39-33.81; P = .0179), and periprocedural heparin use (OR 5.89; 95% CI 1.34-25.92; P = .0189). CONCLUSIONS: In this small subgroup of the Multi MERCI trial, periprocedural heparin use in acute ischemic stroke endovascular therapy was not associated with increased rates of intracerebral hemorrhage or 90-day mortality. The improved 90-day good outcome among patients undergoing mechanical thrombectomy combined with periprocedural heparin warrants further study in a larger cohort.
Authors: Jens Fiehler; Michael Söderman; Francis Turjman; Philip M White; Søren Jacob Bakke; Salvatore Mangiafico; Rüdiger von Kummer; Mario Muto; Christophe Cognard; Jan Gralla Journal: Neuroradiology Date: 2012-09-05 Impact factor: 2.804
Authors: Marc A Lazzaro; Roberta L Novakovic; Andrei V Alexandrov; Ziad Darkhabani; Randall C Edgell; Joey English; Donald Frei; Dara G Jamieson; Vallabh Janardhan; Nazli Janjua; Rashid M Janjua; Irene Katzan; Pooja Khatri; Jawad F Kirmani; David S Liebeskind; Italo Linfante; Thanh N Nguyen; Jeffrey L Saver; Lori Shutter; Andrew Xavier; Dileep Yavagal; Osama O Zaidat Journal: Neurology Date: 2012-09-25 Impact factor: 9.910
Authors: V Da Ros; J Scaggiante; F Sallustio; S Lattanzi; M Bandettini; A Sgreccia; C Rolla-Bigliani; E Lafe; G Sanfilippo; M Diomedi; M Ruggiero; N Haznedari; M Giannoni; C Finocchi; R Floris Journal: AJNR Am J Neuroradiol Date: 2020-09-24 Impact factor: 3.825
Authors: Diogo C Haussen; Ivan M Ferreira; Clara Barreira; Jonathan A Grossberg; Francesco Diana; Simone Peschillo; Raul G Nogueira Journal: Interv Neurol Date: 2018-06-08
Authors: Vicky Chalos; Rob A van de Graaf; Bob Roozenbeek; Adriaan C G M van Es; Heleen M den Hertog; Julie Staals; Lukas van Dijk; Sjoerd F M Jenniskens; Robert J van Oostenbrugge; Wim H van Zwam; Yvo B W E M Roos; Charles B L M Majoie; Hester F Lingsma; Aad van der Lugt; Diederik W J Dippel Journal: Trials Date: 2020-07-14 Impact factor: 2.279
Authors: Rob A van de Graaf; Vicky Chalos; Gregory J Del Zoppo; Aad van der Lugt; Diederik W J Dippel; Bob Roozenbeek Journal: Front Neurol Date: 2018-04-16 Impact factor: 4.003